Patients diagnosed with malignant mesothelioma have new reason for hope, as the U.S. Food and Drug Administration has granted fast track designation to SynKIR-110, a new drug for the treatment of the rare, asbestos-related form of cancer.
Mesothelioma Meets the Criteria for Fast-Track Drugs
Malignant pleural mesothelioma is an extremely rare and aggressive form of cancer, and even the most effective treatments have proven unable to stop it from claiming its victims’ lives. Fast-track designation is a process meant to expedite the review of new drugs in order to meet this type of unmet need with the hope that drug manufacturers who develop new approaches will be able to get them to patients faster.
This week, SynKIR-110 was granted fast track status for use in the treatment of mesothelioma. Created by Verismo Therapeutics, the drug uses a modified NK-like receptor to improve the persistence and effectiveness of treatments used for aggressive solid tumors. Animal tests have shown that even cases where traditional CAR-T cell therapies have been less effective have shown sustained antitumor T-cell activity when the dual-chain CAR T-cell therapy has been used.
Drug Can be Used with a Variety of Innovative Mesothelioma Treatments
One of the most promising aspects of SynKIR-110 is that it can be used in conjunction with many different types of mesothelioma treatments, including combination therapies, advanced cell manufacturing, and in vivo gene engineering. Speaking of the drug’s new status, Bryan Kim, DMD, co-founder and chief executive officer of Verismo Therapeutics, said, “We are thrilled to receive fast track designation from the FDA. This designation is an important milestone in our efforts to bring this potentially life-saving drug to patients who are in need of new treatment options.”
If you or someone you love has been diagnosed with malignant mesothelioma and you want more information on innovative treatment options, contact the Patient Advocates at Mesothelioma.net today at 1-800-692-8608.
